doxazosin has been researched along with Elevated Cholesterol in 24 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting." | 9.08 | Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996) |
| "Hypertension treatment with doxazosin or HCTZ resulted in a comparable change in arterial IMT after three years, in spite of differences in effect on plasma lipids." | 5.10 | Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. ( Birkenhägeri, JC; de Groot, E; de Heide, LH; de Ridder, MA; Hoogerbrugge, N; Jansen, H; Stijnen, T, 2002) |
| " The double-blind, active-controlled component of ALLHAT was designed to determine whether the rate of the primary outcome-a composite of fatal coronary heart disease and nonfatal myocardial infarction-differs between diuretic (chlorthalidone) treatment and each of three other classes of antihypertensive drugs: a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin) in high-risk hypertensive persons ages 55 years and older." | 5.09 | Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT, 2001) |
| "The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)." | 5.09 | Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001) |
| "The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting." | 5.08 | Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996) |
| " In this multicenter open-label study, the long-term effects of doxazosin, an alpha 1-adrenergic receptor blocker, on serum lipids were prospectively investigated in 253 patients with essential hypertension." | 5.08 | Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. ( Ebihara, A; Fujimura, A; Ishimitsu, T; Murata, K; Saito, A; Sakamaki, T; Sugishita, Y; Yagi, S, 1996) |
| " With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity." | 3.69 | [Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995) |
| "The effect of doxazosin administration on hemodynamics, hemostasis, and serum lipid and lipoprotein levels was investigated in cynomolgus monkeys (Macaca fascicularis) with diet-induced hypercholesterolemia." | 3.67 | Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys. ( Karge, WH; Kowala, MC; Nicolosi, RJ; Weiner, EJ, 1989) |
| "Hypertension and hypercholesterolemia are frequently associated with this leading to considerable cardiovascular risk." | 2.67 | [Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme]. ( Alcázar de la Osa, JM; Fernández Pinilla, C; Luque Otero, M; Martell Claros, N; Rodicio Díaz, JL; Ruilope Urioste, LM, 1993) |
| "Because coronary heart disease is known to have many causes, primary preventive therapy must logically go beyond the relatively simple goal of lowering blood pressure." | 2.66 | Effects of oral antihypertensive agents on blood lipid levels. ( Leren, P, 1986) |
| "Doxazosin treatment prevented the impairment in endothelium-dependent vascular relaxation in the high cholesterol/antioxidant-deficient group." | 1.30 | Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. ( Coffee, K; Guerra, J; Hayakawa, H; Raij, L, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (20.83) | 18.7374 |
| 1990's | 14 (58.33) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoogerbrugge, N | 1 |
| de Groot, E | 1 |
| de Heide, LH | 1 |
| de Ridder, MA | 1 |
| Birkenhägeri, JC | 1 |
| Stijnen, T | 1 |
| Jansen, H | 2 |
| Wilson, TA | 1 |
| Foxall, TL | 2 |
| Nicolosi, RJ | 4 |
| Moiseev, VS | 1 |
| Ivleva, AIa | 1 |
| Kobalava, ZhD | 1 |
| Stucchi, AF | 2 |
| Vespa, DB | 1 |
| Terpstra, AH | 1 |
| Fernández Pinilla, C | 1 |
| Luque Otero, M | 1 |
| Martell Claros, N | 1 |
| Alcázar de la Osa, JM | 1 |
| Rodicio Díaz, JL | 1 |
| Ruilope Urioste, LM | 1 |
| Ferrara, LA | 1 |
| Di Marino, L | 1 |
| Russo, O | 1 |
| Marotta, T | 1 |
| Mancini, M | 1 |
| Levy, D | 1 |
| Walmsley, P | 1 |
| Levenstein, M | 1 |
| Ishimitsu, T | 1 |
| Yagi, S | 1 |
| Sugishita, Y | 1 |
| Fujimura, A | 1 |
| Ebihara, A | 1 |
| Sakamaki, T | 1 |
| Murata, K | 1 |
| Saito, A | 1 |
| Raij, L | 1 |
| Hayakawa, H | 1 |
| Coffee, K | 1 |
| Guerra, J | 1 |
| Grzeszczak, W | 1 |
| Martínez-Castelao, A | 1 |
| Hueso, M | 1 |
| Sanz, V | 1 |
| Rejas, J | 1 |
| Alsina, J | 1 |
| Grinyó, JM | 1 |
| SoRelle, R | 1 |
| Pressel, SL | 1 |
| Davis, BR | 2 |
| Wright, JT | 1 |
| Geraci, TS | 1 |
| Kingry, C | 1 |
| Ford, CE | 1 |
| Piller, LB | 1 |
| Bettencourt, J | 1 |
| Kimmel, B | 1 |
| Lusk, C | 1 |
| Parks, H | 1 |
| Simpson, LM | 1 |
| Nwachuku, C | 1 |
| Furberg, CD | 1 |
| Barzilay, JI | 1 |
| Jones, CL | 1 |
| Basile, JN | 1 |
| Goff, DC | 1 |
| Ciocon, JO | 1 |
| Sweeney, ME | 1 |
| Randall, OS | 1 |
| Macphee, GJ | 1 |
| Curzio, J | 1 |
| Farish, E | 1 |
| Reid, JL | 1 |
| Elliott, HL | 1 |
| Shwaery, GT | 1 |
| Wong, SS | 1 |
| Jansson, JH | 1 |
| Johansson, B | 1 |
| Boman, K | 1 |
| Nilsson, TK | 1 |
| Pool, JL | 1 |
| Lenz, ML | 1 |
| Taylor, AA | 1 |
| Karge, WH | 1 |
| Kowala, MC | 1 |
| Weiner, EJ | 1 |
| Lammers, R | 1 |
| Baggen, MG | 1 |
| Penders, JM | 1 |
| Birkenhäger, JC | 1 |
| Leren, P | 1 |
| Swindell, AC | 1 |
| Valentine, JJ | 1 |
| Leren, TP | 1 |
| Berg, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for doxazosin and Elevated Cholesterol
| Article | Year |
|---|---|
[Use of doxazosin (Cardura-Pfizer), alpha 1-adrenoreceptor antagonist, in treatment of hypertension in patients with diabetes].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Diabetic Angiopathies; Doxazosin; Humans; Hyperc | 1998 |
13 trials available for doxazosin and Elevated Cholesterol
| Article | Year |
|---|---|
Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Disease Progression; Diuretics; D | 2002 |
Combined effect of a low fat diet and doxazosin on blood pressure control and blood lipids. Hunter Hypertension Research Group.
Topics: Adult; Aged; Blood Glucose; Blood Pressure Monitoring, Ambulatory; Diet, Fat-Restricted; Doxazosin; | 1994 |
[Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme].
Topics: Adult; Aged; Doxazosin; Enalapril; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle | 1993 |
Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study.
Topics: Adult; Aged; Blood Pressure; Captopril; Doxazosin; Female; Heart Rate; Humans; Hypercholesterolemia; | 1993 |
Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dis | 1996 |
Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Antihypertensive Agents; Bloo | 1996 |
Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin.
Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Doxazosin; Enalapril; Female; Follow-Up St | 1998 |
National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Chlorthalidone; Diuretics; Doxazosin; Female | 2000 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; | 2001 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant | 2001 |
Placebo-controlled trial of doxazosin in management of patients with hypertension and hypercholesterolaemia.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cholesterol; Doxazosin; Female; Humans; Hypercholeste | 1992 |
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi | 1991 |
Effects of oral antihypertensive agents on blood lipid levels.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cl | 1986 |
10 other studies available for doxazosin and Elevated Cholesterol
| Article | Year |
|---|---|
Doxazosin, an alpha-1 antagonist, prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters.
Topics: Adrenergic alpha-Antagonists; Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholestero | 2003 |
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin; | 1995 |
Effects of doxazosin, an alpha 1-adrenergic inhibitor, on plasma lipid and lipoprotein levels, low density lipoprotein metabolism and cholesterol absorption in cynomolgus monkeys.
Topics: Absorption; Animals; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholester | 1993 |
Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Doxazosin; Endothelium, Vascular; | 1997 |
Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
Topics: Adrenergic alpha-Antagonists; Animals; Aortic Diseases; Arteriosclerosis; Cricetinae; Dose-Response | 1992 |
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
Topics: Adrenergic alpha-Antagonists; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dox | 1990 |
Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
Topics: Adrenergic alpha-Antagonists; Animals; Apolipoproteins B; Disease Models, Animal; Doxazosin; Hemodyn | 1989 |
Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster.
Topics: Acetates; Adrenergic alpha-Antagonists; Animals; Cholesterol; Cholesterol, Dietary; Cricetinae; Doxa | 1989 |
Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/cdJ mice.
Topics: Adrenergic alpha-Antagonists; Animals; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Dise | 1987 |
Studies of serum lipids in hypercholesterolaemic rabbits treated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Chinchilla; Cholesterol; Doxazosin; Drug Evaluation, Preclini | 1988 |